Puberty Suppression and Cardiometabolic Health

Part of paid clinical trials in Aurora, Colorado.

Sponsor
University of Colorado, Denver
Study ID
NCT04482374
Status
Recruiting
Apply to this trial

Conditions

  • Endothelial Dysfunction
  • Insulin Sensitivity/Resistance
  • Transgenderism
  • Vascular Stiffness

Eligibility Criteria

Sex
MALE
Age
9 Years - 14 Years
Healthy Volunteers
Not accepted

Study Details

This observational study will evaluate the effect of puberty suppression on insulin sensitivity, metabolic rate and vascular health among transgender female youth at baseline and 6 months after initiation of a gondoatropin releasing hormone agonist compared to matched cisgender male controls.

Key Dates

Start date
Aug 10, 2020
Status verified
Jun 2025
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
30 participants (estimated)

Arms

  • Arm: Transgender females
    Transgender females who plan to start a gonadotropin releasing hormone agonist clinically in the next 2 months
  • Arm: Cisgender males
    Cisgender male controls

Primary Outcome Measure

Change in insulin sensitivity [ Time Frame: Baseline, 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Colorado Anschutz Medical CampusAuroraColorado80045
Natalie Nokoff, MD, MSCS
[email protected]
720-777-3607

Find similar trials in Aurora, CO

By research site
University of Colorado Anschutz Medical Campus· Aurora, CO

Related Studies